

USA Moves to Reschedule Cannabis to a Schedule III

On May 15, the US Justice Department took a significant step towards rescheduling cannabis federally from a Schedule I to a Schedule III substance. President Joe Biden announced his support for the reclassification in a video posted to his official X account. “This is monumental,” Biden said. “It’s an important move towards reversing long-standing inequities. Far too many lives have been upended because of a failed approach to marijuana, and I’m committed to righting those wrongs. You have my word on it.”

Acknowledging Medical Benefits

The Biden administration has been signaling that it would try to reschedule marijuana from a Schedule I — a strict classification that includes drugs like heroin — to the less-stringent Schedule III. This reclassification would, for the first time, acknowledge the substance’s medical benefits at the federal level. Such a change would significantly impact the legal landscape for cannabis, facilitating research and potentially altering its availability and regulation.

Public Comment Period Initiated

The Drug Enforcement Administration (DEA) submitted a notice of proposed rulemaking in the Federal Register on Thursday afternoon. This action triggers a 60-day public comment period, allowing the public to submit remarks regarding the rescheduling proposal before it is finalized. This period is crucial for gathering input from various stakeholders, including medical professionals, researchers, advocates, and the general public, ensuring a comprehensive review of the proposed changes.

Potential Impacts of Rescheduling

Reclassifying cannabis as a Schedule III drug would have several significant impacts. Firstly, it would facilitate research into the medical benefits and potential risks of cannabis, as Schedule I status has long hindered scientific studies. Additionally, it would allow for greater access to banking and financial services for the cannabis industry, which has faced challenges due to the federal prohibition.

Addressing Long-Standing Inequities

President Biden’s announcement emphasizes the administration’s commitment to addressing the long-standing inequities associated with the criminalization of marijuana. By rescheduling cannabis, the federal government acknowledges the disproportionate impact that the war on drugs has had on minority communities. This move is seen as a step towards justice and equity in drug policy.

Moving Forward

The rescheduling of cannabis is not yet finalized, and the next 60 days will be critical in determining the outcome. During this time, the public and various stakeholders are encouraged to participate in the comment period to ensure that all perspectives are considered. As the process unfolds, it is clear that this move marks a pivotal moment in the ongoing evolution of US drug policy.

The Biden administration's efforts to reclassify cannabis reflect a broader shift towards evidence-based policy and a recognition of the need for reform in the nation's approach to drug regulation. The potential rescheduling of cannabis as a Schedule III substance signifies a historic step in the right direction, promising to reshape the future of cannabis in America.

Email: info@cannabisriskmanager.com | Phone: +415-226-4060

© Copyright 2025 Cannabis Risk Manager. All Rights Reserved